Corporate presentation
Logotype for KORU Medical Systems Inc

KORU Medical Systems (KRMD) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for KORU Medical Systems Inc

Corporate presentation summary

16 Nov, 2026

Business and platform

  • Enables large-volume subcutaneous drug delivery at home and in clinics, supporting the shift from hospital-based IV therapy to patient-administered care.

  • Freedom Infusion System serves ~60,000 chronic patients and supports ~2.7M annual recurring infusions; weekly SCIg treatment is typically ongoing for chronic conditions.

  • Seven SCIg drugs from four major pharmaceutical manufacturers are cleared for use; Freedom60 and FreedomEDGE also have 510(k) clearance and MDR approval for prefilled syringes.

  • Product mix is ~20% mechanical pumps and ~80% customizable consumables; cited patient adherence rate is 97%.

Market opportunity and pipeline

  • Large-volume SC opportunity includes a growing SCIg market with <20% penetration versus IVIg, plus 95+ drugs in development at volumes above 10 mL.

  • Estimated market opportunity is ~$60M in 2025 and ~$138M by 2030; 13 drugs launched during 2020–2026, diversifying the market mainly into oncology.

  • Pipeline includes eight active new-drug or indication opportunities and nine drugs on the system label; estimated annual infusion volumes include 5.4M for SCIg and <0.25M for non-SCIg drugs.

  • Near-term opportunities include deferoxamine, Phesgo, Empaveli for FSGS and DGF, and enzyme therapy; estimated launch windows span 0–1, 1–3 and 3–5 years.

Financial performance

  • FY2025 revenue was $41.1M; FY2026 guidance is $48M–$48.5M, 17–18% YoY growth, 63–64% gross margin, positive adjusted EBITDA and year-end cash above $8M.

  • YTD 2026 revenue was $35.4M, up 17%; gross margin was 64.0%, up 190 bps, and operating expenses were 64.1% of sales, a 620 bps improvement YoY.

  • YTD 2026 net loss was $0.3M versus $2.2M; adjusted EBITDA was $2.2M versus $0.1M, while cash usage was $1.5M and included a ~$1M Q2 technology acquisition.

  • Long-term goals include $100M revenue, accelerated double-digit revenue CAGR, gross margin above 65% and EBITDA margin above 20%.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from KORU Medical Systems